Table 3.

Clinical characteristics of CRS subgroups.

	E (n =19)	LP (n =104)	E+LP (n=31)	N+LP (n=4)	χ2	P
Age	47 (36,59)	37 (29.25,52.75)	37 (29,48)	44.5 (22.25,64.5)	2.971	0.396
Gender (M/F)	14/5	77/27	23/8	3/1	0.222	1.000
Onset time (months)	60 (24,120)	48 (12,120)	36(12,120)	39 (4.5,288)	1.142	0.767
Itching (Y/N)	8/11	15/89	20/11	0/4	31.306	<0.001*
Sneezing (Y/N)	8/11	17/87	21/10	0/4	31.334	0.013*
Asthma (Y/N)	4/15	4/100	5/26	0/4	9.106	0.016*
Rhinorrhea score	6 (5,7)	6 (5,7)	6 (5,7)	6 (3,6.75)	1.298	0.730
Nasal obstruction score	6 (6,7)	6 (5,6.75)	6 (5,6)	6 (5.25,6.75)	3.578	0.311
Olfactory dysfunction score	6 (5,7)	5 (2.25,6)	6 (3,8)	6 (2.25,6.75)	7.058	0.070
Headache/facial pain score	2 (1,6)	2 (1,4.75)	3 (1,5)	3 (0.25,5)	1.473	0.689
Total VAS score	21 (19,24)	19 (15,21)	21 (15,24)	21.5 (10.75,24.75)	6.397	0.094
Lund-Kennedy score	8 (6,10)	8 (5,10)	6 (4,10)	6.5 (4.5,10.75)	1.737	0.629
Lund-Mackay score	11 (9,16)	11 (8,18)	10 (8,14)	16 (8,19.5)	1.360	0.715
Total IgE (IU/ml) (1^/2#/3&)	5/3/11	59/12/33	5/14/12	4/0/0	15.878	0.001*
Peripheral lym%	31.9 (29.09,34.32)	32.7 (28.45,39.05)	31.72 (27.48,36.92)	31.49 (27.89,32.07)	2.865	0.413
Peripheral neu%	53.17 (49.25,57.06)	54.85 (48.24,59.92)	49.16 (45.56,56.31)	55.29 (51.1,61.55)	5.452	0.142
Peripheral eos%	6.9 (3.5,9.87)	2.9 (1.84,5)	7.48 (5.23,9.66)	4.32 (1.9,6.18)	40.377	<0.001*
Peripheral bas%	0.46 (0.33,0.96)	0.58 (0.34,0.66)	0.71 (0.38,0.96)	0.48 (0.28,1.13)	3.355	0.340
Recurrence$ (Y/N)	12/4	5/66	15/11	1/2	44.459	<0.001*

E= eosinophil-dominant phenotypes; LP: plasma cells and lymphocyte-dominant phenotypes;

E+LP= eosinophils, plasma cells and lymphocyte-dominant phenotypes;

N+LP= neutrophils, plasma cells and lymphocyte-dominant phenotypes;

1^, Total IgE<100 IU/ml; 2^#, 100 IU/ml <Total IgE<200 IU/ml; 3^&, Total IgE>200 IU/ml.

^$data from a retrospective cohort.

*P<0.05.